Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents
- PMID: 27549098
- DOI: 10.2174/1389557516666160822110819
Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents
Abstract
As one of the leading causes of deaths worldwide, cancer is posing threat despite efforts being taken to develop effective anticancer drugs. There is an increase in number of chemotherapy treatments due to growing number of manifestations causing increasing toxicities of cytotoxic agents. Almost all the anticancer agents available till date have one or the other side effects. Topoisomerases are the attractive targets to develop effective anticancer agents. There has been development of many topoisomerase inhibitors till date and has shown good anticancer activity but their side effects outnumber their anticancer potential. Hence, there is an urgent need to develop effective therapeutic agents with fewer side effects. This review deals with design and development aspect of topoisomerase inhibitors as exciting novel anticancer agents. The emphasis has been laid in particular on the new potential heterocyles as TOP inhibitors in the field of medicinal chemistry. The review discusses about the topoisomerase poisons, TOP1 suppressors, TOP inhibitors and Dual TOP 1/2 inhibitors.
Similar articles
-
Topoisomerase as target for antibacterial and anticancer drug discovery.J Enzyme Inhib Med Chem. 2013 Jun;28(3):419-35. doi: 10.3109/14756366.2012.658785. Epub 2012 Mar 1. J Enzyme Inhib Med Chem. 2013. PMID: 22380774 Review.
-
Topoisomerases as anticancer targets.Biochem J. 2018 Jan 23;475(2):373-398. doi: 10.1042/BCJ20160583. Biochem J. 2018. PMID: 29363591 Free PMC article. Review.
-
DNA topoisomerases as molecular targets for anticancer drugs.J Enzyme Inhib Med Chem. 2020 Dec;35(1):1781-1799. doi: 10.1080/14756366.2020.1821676. J Enzyme Inhib Med Chem. 2020. PMID: 32975138 Free PMC article. Review.
-
Benzimidazole Scaffold as Anticancer Agent: Synthetic Approaches and Structure-Activity Relationship.Arch Pharm (Weinheim). 2017 Jun;350(6). doi: 10.1002/ardp.201700040. Epub 2017 May 22. Arch Pharm (Weinheim). 2017. PMID: 28544162 Review.
-
Topoisomerase Inhibitors and Targeted Delivery in Cancer Therapy.Curr Top Med Chem. 2019;19(9):713-729. doi: 10.2174/1568026619666190401112948. Curr Top Med Chem. 2019. PMID: 30931860 Review.
Cited by
-
Preparation of Enzyme-Activated Thapsigargin Prodrugs by Solid-Phase Synthesis.Molecules. 2018 Jun 15;23(6):1463. doi: 10.3390/molecules23061463. Molecules. 2018. PMID: 29914143 Free PMC article.
-
Chromatin dependencies in cancer and inflammation.Nat Rev Mol Cell Biol. 2018 Apr;19(4):245-261. doi: 10.1038/nrm.2017.113. Epub 2017 Nov 29. Nat Rev Mol Cell Biol. 2018. PMID: 29184195 Review.
-
Personalized Prescription of Chemotherapy Based on Assessment of mRNA Expression of BRCA1, RRM1, ERCC1, TOP1, TOP2α, TUBβ3, TYMS, and GSTP1 Genes in Tumors Compared to Standard Chemotherapy in the Treatment of Non-Small-Cell Lung Cancer.J Pers Med. 2022 Oct 4;12(10):1647. doi: 10.3390/jpm12101647. J Pers Med. 2022. PMID: 36294786 Free PMC article.
-
Polymer-Drug Conjugate, a Potential Therapeutic to Combat Breast and Lung Cancer.Pharmaceutics. 2020 Apr 29;12(5):406. doi: 10.3390/pharmaceutics12050406. Pharmaceutics. 2020. PMID: 32365495 Free PMC article. Review.
-
Study on the expression of TOP2A in hepatocellular carcinoma and its relationship with patient prognosis.Cancer Cell Int. 2022 Jan 15;22(1):29. doi: 10.1186/s12935-021-02439-0. Cancer Cell Int. 2022. PMID: 35033076 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials